GE HealthCare Technologies Inc. has announced the launch of CleaRecon DL, an advanced AI-based solution designed to enhance the quality of cone-beam computed tomography (CBCT) images. Powered by a deep-learning algorithm, CleaRecon DL aims to remove streak artifacts caused by blood flow and contrast distribution changes during CBCT acquisitions in various medical procedures, including liver and prostate interventions. The technology has received U.S. FDA 510(k) clearance and a CE mark, allowing clinicians to leverage 3D image guidance technologies more effectively. This advancement is expected to improve clinical confidence and encourage the adoption of CBCT, ultimately enhancing patient care. CleaRecon DL will be showcased at the Global Embolization Symposium & Technologies (GEST) 2025 Annual Meeting in New York.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.